Circulating biomarkers to monitor cancer progression and treatment
Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still, the standard diagnostic approach relies on the analysis of a single tumor sample from a local or metastatic site that is obtained at a given time point. Due to intratumoral heterogeneity and selection of s...
Main Authors: | Suthee Rapisuwon, Eveline E. Vietsch, Anton Wellstein |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037016300113 |
Similar Items
-
Circulating cell-free nucleic acids of plasma in human aging, healthy aging and longevity: current state of knowledge
by: Nicolas P. Tessier, et al.
Published: (2023-11-01) -
Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective
by: Sridhar Mishra, et al.
Published: (2024-12-01) -
Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
by: Pablo J. Dopico, et al.
Published: (2022-03-01) -
New Year, New Name and New Milestones Scope - Journal of Circulating Biomarkers
by: Shidong Jia, et al.
Published: (2014-04-01) -
Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer
by: Anelis Maria Marin, et al.
Published: (2023-04-01)